Lenalidomide has demonstrated the ability to enhance the therapeutic efficacy of anti-CS1 or anti-BCAM, anti-CD19, anti-CD23, and anti-WT1 CAR T-cells in preclinical models of MM, DLBCL, CLL, and AML, respectively. Here, CD19 is linked to Miyoshi myopathy.